Image Source: MedPage Today
Topics: Biology, Biotechnology, Civilization, COVID-19, DNA, Epidemiology
Currently authorized bivalent COVID-19 boosters demonstrated similar protection against symptomatic illness from the XBB/XBB.1.5 Omicron subvariants as from BA.5-related subvariants, according to a CDC study.
From December 2022 to January 2023, the bivalent boosters' vaccine effectiveness (VE) against symptomatic infection was a similar 48% versus XBB/XBB.1.5-related strains and 52% versus BA.5-related sublineages, reported Ruth Link-Gelles, Ph.D., of the CDC's National Center for Immunization and Respiratory Diseases, and colleagues in Morbidity and Mortality Weekly Report (MMWR).
Meanwhile, Pfizer's updated booster demonstrated superior neutralizing antibody activity compared with the company's original product against all the latest Omicron subvariants, including XBB.1, according to Kena Swanson, Ph.D., of Pfizer Vaccine Research and Development in Pearl River, New York and colleagues, writing in the New England Journal of Medicine. Their findings contradict earlier research from other labs that found no significant difference in neutralizing activity with the bivalent over the monovalent vaccine.
According to the latest estimates from the CDC, XBB.1.5 is responsible for 49.1% of new COVID-19 cases in the U.S., while XBB is responsible for another 3.3%.
— And Pfizer lab data show better neutralization against the latest variants with the bivalent shot, Ingrid Hein, Staff Writer, MedPage Today